Starting Treatment

Getting started on treatment.

Now that you and your doctor have decided to explore treatment with VYONDYS 53, you probably have questions about what comes next. We’ll guide you along the way so you’ll know just what to expect.

Let's START

 

 

 

 

 

  1. Investigating Your Coverage

    Find out how SareptAssist, our patient support program, can help you get answers to questions about insurance benefits and verify coverage with your insurance company. Learn More

     

  2. Planning for Treatment

    Learn about creating a treatment plan that works for your family to help make the process go as smoothly as possible. Learn More

     

  3. About the Infusion

    Let’s take the mystery out of infusions. Here’s an overview of what they’re like, from start to finish. Learn More

     

  4. Ongoing Support

    It’s important to get ongoing support throughout treatment. SareptAssist will connect you with a dedicated Case Manager to help you start and stay on treatment. Learn More

 

Meet the SareptAssist Team.

Watch this video to learn more about the one-on-one personalized support offered to you by SareptAssist.

SareptAssist is a resource available to those pursuing or currently utilizing one of Sarepta's approved products. SareptAssist is only available in the United States.

 

 

Ongoing support and information from Sarepta.

Sign Up

Icon Signup tips

Receive future tips and support about treatment with VYONDYS 53.

Icon Signup Informed

Stay informed about SareptAssist services.

An icon of 3 people and a circle

Find out about patient resources that are available.

envelope

Get updates about news and research on Duchenne from Sarepta.

 

 

WHAT IS VYONDYS 53 (golodirsen)?

VYONDYS 53 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 53.

This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

Read More

IMPORTANT RISK INFORMATION

Allergic reactions, including rash, fever, itching, hives, and inflammation and/or peeling of the skin have occurred in patients who were treated with VYONDYS 53. Seek immediate medical care if signs and symptoms of allergic reactions occur.

Damage to the kidneys was seen in animals who received golodirsen. Although damage to the kidneys was not seen in clinical studies with VYONDYS 53, potentially fatal kidney damage has occurred with other drugs that work in a similar way. Your doctor may recommend urine and blood testing before starting treatment followed by urine testing every month and a blood test every 3 months to monitor your kidneys.

IMPORTANT RISK INFORMATION

Allergic reactions, including rash, fever, itching, hives, and inflammation and/or peeling of the skin have occurred in patients who were treated with VYONDYS 53.  Seek immediate medical care if signs and symptoms of allergic reactions occur.

Damage to the kidneys was seen in animals who received golodirsen. Although damage to the kidneys was not seen in clinical studies with VYONDYS 53, potentially fatal kidney damage has occurred with other drugs that work in a similar way. Your doctor may recommend urine and blood testing before starting treatment followed by urine testing every month and a blood test every 3 months to monitor your kidneys.

Adverse reactions that have occurred in at least 20% of patients treated with VYONDYS 53 and more often than in patients who received an inactive intravenous (IV) infusion were headache (41%, 10%), fever (41%, 14%), fall (29%, 19%), pain in the abdomen (27%, 10%), infection of the nose and throat (27%, 14%), cough (27%, 19%), vomiting (27%, 19%), and nausea (20%, 10%).

Other adverse reactions that occurred in greater than 5% of patients treated with VYONDYS 53 and more often than in patients who received an inactive IV infusion were pain at the IV site, back pain, pain, diarrhea, dizziness, stretch or tear in a ligament, bruising, flu, pain in the mouth and throat, stuffy or runny nose, scrapes or scratches of the skin, ear infection, seasonal allergy, fast heartbeat, reactions related to the IV catheter site, constipation, and broken bones.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

Please see the full Prescribing Information for VYONDYS 53 (golodirsen).